鲁索替尼乳膏Opzelura治疗特应性皮炎的疗效怎么样？

The US FDA has approved ruxolitinib cream Opzelura for short-term and discontinuous long-term treatment of patients over 12 years of age with mild to moderate atopic dermatitis (AD). Ruxolitinib cream Opzelura is a JAK1/JAK2 selective inhibitor that modulates the activity of inflammatory factors related to the pathology of atopic dermatitis and may directly modulate itching. How effective is it in treating atopic dermatitis?

Ruxolitinib cream Opzelura is the first FDA-approved topical JAK inhibitor. The US FDA's approval was based on two randomized, double-blind, vehicle-controlled Phase 3 clinical trials, including more than 1,200 adolescent and adult patients with mild to moderate AD. The trial results showed that at the 8th week of treatment, compared with the vehicle group, a significantly higher proportion of patients in the 1.5% ruxolitinib cream group achieved IGA-TS treatment success; a higher proportion of patients in the 1.5% ruxolitinib cream group achieved EASI75 (Eczema Area and Severity Index score improved by ≥75% from baseline). Combining the data from the two trials, it can be seen that the therapeutic effect of ruxolitinib cream Opzelura is significant. This drug can improve the patient's eczema area, reduce the severity of the condition, improve the patient's quality of life, and has a positive effect on the patient's condition. Note to patients: It is not recommended to use Ruxolitinib Cream Opzelura in combination with therapeutic biologics, other JAK inhibitors, or strong immunosuppressants, as this may affect the therapeutic effect of the drug.

The above is an introduction to Ruxolitinib Cream Opzelura. If patients want to know more drug information about Ruxolitinib Cream Opzelura (such as usage, precautions, drug prices, purchase channels, etc.), they can consult the Medical Companion Travel Service.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended hot articles: